Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2001

View Archived Issues

Vical and Ichor form collaboration on gene-based delivery of therapeutic proteins

Lexicon grants license to DNA technology for gene targeting

GSK seeks Swedish approval of dutasteride for treatment of BPH

Preclinical studies of Inactine system demonstrate ability to reduce RBC prion proteins

Caspase inhibitor protects myocardium during septic shock by inhibiting myocyte apoptosis

Alizyme highlights product development efforts

European launch of Thyrogen under way

ESICM highlights: pharmacokinetics of drotrecogin alfa determined in PROWESS

InterMune and Boehringer Ingelheim expand partnership to develop product for ovarian cancer

Unigene awarded federal grant to aid in developing hormone for osteoporosis

Amarillo Biosciences receives grant to develop H. pylori vaccine

Further evidence indicating enhanced antiinflammatory activity for NO-releasing steroid

GSK seeks European approval of Seretide for COPD

Strontium ranelate has dual bone formation-enhancing and antiresorptive effects

Positive phase II results reported for methylnaltrexone

FDA grant and European OMP designation for Fibrillex

Mast cell chymase inhibitors discovered at Teijin

Aromatherapy shows no benefit over placebo in postoperative nausea

Cholinergic function modulators claimed for use in nicotine addiction and other disorders by Pfizer

Fujisawa identifies new aminoalcohol beta3-adrenoceptor agonists

Preparation and use of A2A receptor agonists in heart imaging

Intranasal morphine tested for relief of breakthrough pain in cancer patients

FDA clears use of Allergan's Tazorac cream for treatment of acne

Ortho-McNeil patents new series of neuropeptide Y5 receptor ligands

Hydroxamic acid-based inhibitors of sCD23 formation and TNF processing

Patent coverage gained for Gliatech's antiproperdin antibody therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...